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OBJECTIVES This study was designed to investigate the impact of percutaneous coronary interventions
(PCIs) in degenerated saphenous vein grafts (SVGs) without distal embolic protection.
BACKGROUND Distal embolic protection devices have been shown to reduce the incidence of no reflow/slow
flow during PCI of de novo lesions in degenerated SVGs. It is unclear whether PCI of
in-stent restenosis (ISR) lesions in degenerated SVGs is associated with no reflow/slow flow
and whether distal embolic protection is beneficial in these cases as well.
METHODS We studied 54 consecutive patients with treated ISR lesions in degenerated SVGs who
underwent PCI without distal embolic protection in a single center. Procedural and
in-hospital outcomes were examined.
RESULTS The average age was 71  8 years; 32% of the patients had diabetes. The mean lesion length
was 13 6 mm and the procedural success rate was 98% (53/54). Cutting balloon angioplasty
was used in 46% (25/54) of cases, and a new stent was inserted in 46% (25/54) of patients.
Gamma brachytherapy was performed in 19% (10/54) of patients. During the procedure there
were no episodes of no reflow/slow flow, and there were no patients with in-hospital Q-wave
or non–Q-wave myocardial infarction. There was one in-hospital noncardiac death.
CONCLUSIONS In this consecutive series of patients with ISR of degenerated SVGs undergoing PCI without
distal protection, there were no episodes of slow flow/no reflow and no procedure-related
myocardial infarctions. It appears that distal embolic protection may not be necessary during
PCI of ISR lesions in degenerated SVGs. (J Am Coll Cardiol 2003;41:749–52) © 2003 by
the American College of Cardiology Foundation
The absence of blood flow or decreased blood flow (no
flow/slow flow) is a serious complication of percutaneous
revascularization strategies that may result in an increased
incidence of morbidity and mortality (1). The risk of
coronary no reflow/slow flow is markedly increased in
interventions of degenerated saphenous vein grafts (SVGs)
and occurs in up to 20% of cases (1,2). Distal embolic
protection devices have been shown to reduce the incidence
of no reflow/slow flow and procedure-related myocardial
infarction (MI) in percutaneous coronary intervention
(PCI) of de novo lesions in degenerated SVGs (3).
In-stent restenosis (ISR) has different tissue pathology
compared to a de novo obstructive atherosclerotic lesion (4).
The ISR lesion consists predominantly of neointimal
smooth muscle cells (5,6) and may be less likely to result in
distal embolization of debris during the PCI procedure.
Given the potential decreased risk of distal embolization for
PCI of ISR lesions, we hypothesized that distal protection
might not be necessary in the treatment of ISR in degen-
erated SVGs. This study investigated the procedural and
in-hospital outcomes of 54 consecutive patients who under-
went PCI for ISR of 54 lesions in degenerated SVGs
without distal protection.
METHODS
All 54 patients were treated at a single center between
January 2000 and December 2001. Patients who had sus-
tained an ST-segment elevation MI in the previous 72 h
were excluded. Degenerated SVGs were defined as SVGs
more than three years old with the presence of extensive
luminal irregularities on the angiogram. Baseline patient
characteristics and in-hospital events were recorded by
independent hospital chart review.
All ISR lesions were classified according to Mehran et al.
(7). Anginal symptoms were classified according to the
Canadian Cardiovascular Society guidelines (8). The choice
of PCI rather than medical or surgical revascularization was
made by the attending cardiologist. Angiographic success
was defined as a reduction of 20% and a50% final residual
diameter stenosis in the lesion. Procedural success was
defined as angiographic success in the absence of major
in-hospital complications (death, Q-wave MI, and emer-
gent bypass surgery). Q-wave MI was defined as the
presence of new Q waves on the postprocedure electrocar-
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diogram (ECG) and a corresponding rise by at least
threefold above normal limits of the serum creatinine kinase
(CK)-MB fraction. Non–Q-wave MI was defined as a rise
by at least threefold above normal limits of the serum
CK-MB fraction without the appearance of new Q waves
on the post-procedure ECG. All patients had post-PCI and
next-day ECGs, and cardiac enzyme determinations at 6 to
8 h and at 16 to 18 h post-PCI.
Angiographic analysis was performed by independent
observers without knowledge of the clinical data using a
validated, automated edge-detection algorithm (CMS,
MEDIS, Leiden, Netherlands) as previously described (9).
No reflow/slow flow conditions were defined using the
Thrombolysis In Myocardial Infarction (TIMI) blood flow
grades (10): no reflow was defined as TIMI 0 to 1 flow and
slow flow as TIMI 2 flow. The use of online intravascular
ultrasound imaging was at the operator’s discretion. Intra-
vascular ultrasound studies were performed with the Boston
Scientific Corporation/Cardiovascular Imaging System as
described previously (11). Vascular brachytherapy was indi-
cated for diffuse ISR, but discouraged if a new stent was
implanted. If a new stent was inserted, ticlopidine (250 mg
twice daily) or clopidogrel (75 mg once daily) was given
routinely for four weeks in addition to aspirin 325 mg,
which was prescribed indefinitely.
Statistical analysis was performed using SAS software
(SAS Institute Inc., Cary, North Carolina). Categorical
data are presented as percent frequencies and compared by
chi-square statistics. Continuous variables are presented as
mean  SD.
RESULTS
The average age was 71  8 years and there were 63% men
patients (Table 1). There were 32% of subjects with a
smoking history, 59% with systemic hypertension, 32% with
diabetes mellitus, and 69% with hypercholesterolemia. Un-
stable angina was present in 44%, and 43% had a history of
prior MI. The mean left ventricular ejection fraction was
decreased at 45 14%.
Angiographic characteristics are shown in Table 2. All
patients had ISR of a single lesion in one degenerated SVG.
The classification of ISR lesions (7) was as follows: focal
(class I) 56% (n  30); intrastent (class II) 19% (n  10);
proliferative (class III) 22% (n  12); total occlusion (class
IV) 4% (n 2). Lesions were located at the aorto-ostium in
20% and within the body of the SVG in 80% of patients;
there were no lesions at the site of the distal anastomosis.
The mean lesion length was 13  6 mm and prediameter
stenosis 77  15%.
The angiographic success was 100%; 19% of the lesions
were treated with balloon angioplasty alone (Table 3), the
cutting balloon was used in 46%, and a new stent was
required in 46% of cases. The rate of glycoprotein IIb/IIIa
inhibitor use was 35%. Intravascular brachytherapy was used
in 10 cases (19%); 8/10 in proliferative lesions (ISR class III)
and 2/10 in the two total occlusions (ISR class IV).
The procedural outcomes and in-hospital events are
shown in Table 4. Procedural success was 98%. There were
no cases of no reflow or slow flow. On the final post-PCI
Table 1. Baseline Clinical Characteristics
Variables Values
Age (yrs) 71  8
Male gender 63% (34/54)
History of smoking 32% (17/54)
Systemic hypertension 59% (32/54)
Diabetes mellitus 32% (17/54)
Family history of CAD 30% (16/54)
Hypercholesterolemia 69% (37/54)
Prior myocardial infarction 43% (23/54)
Unstable angina 44% (24/54)
Prior coronary bypass 100% (54/54)
Prior coronary angioplasty 100% (54/54)
LVEF (%) 45  14
CAD  coronary artery disease; LVEF  left venticula ejection fraction.
Table 2. Angiographic Characteristics
Variables Values
ISR 100% (54/54)
Pattern of ISR (7)
Focal (I) 56% (30/54)
Intrastent (II) 19% (10/54)
Proliferative (III) 22% (12/54)
Total occlusion (IV) 4% (2/54)
Lesion location within SVG
Ostial 20% (11/54)
Within body 80% (43/54)
Distal anastomosis 0% (0/54)
Lesion length (mm) 13.4  6.4
Pre-reference diameter (mm) 3.2  0.6
Pre-diameter stenosis (%) 77  15
Final diameter stenosis (%) 17  18
ISR  in-stent restenosis; SVG  saphenous vein graft.
Table 3. Procedural Characteristics
Variables Values
Angiographic success 100% (54/54)
Plain balloon angioplasty 19% (10/54)
Cutting balloon angioplasty 46% (25/54)
New stent inserted 46% (25/54)
Atherectomy/thrombectomy 0% (0/54)
Glycoprotein IIb/IIIa inhibitor use 35% (19/54)
Intravascular ultrasound guidance 43 (23/54)
Intravascular brachytherapy 19% (10/54)
Abbreviations and Acronyms
CK  creatinine kinase
ECG  electrocardiogram
ISR  in-stent restenosis
MI  myocardial infarction
PCI  percutaneous coronary intervention
SVG  saphenous vein graft
TIMI  Thrombolysis In Myocardial Infarction
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angiogram, TIMI 3 flow was present in all cases. There was
one dissection, which was treated with deployment of a new
stent. There were no cases of threatened or abrupt closure
and no perforations. The final mean activated clotting time
value was 283  76 s. There was only one major in-hospital
event in the 54 patients studied: a patient had a noncardiac
death due to respiratory failure secondary to chronic ob-
structive pulmonary disease and pneumonia. There were no
cases of non–Q-wave or Q-wave MI or repeat revascular-
ization.
DISCUSSION
The no reflow/slow flow phenomenon has been described as
the persistence of abnormally slow myocardial blood flow in
an epicardial coronary artery or vein graft in the absence of
evident vessel dissection, obstruction, or distal vessel cutoff
(1). Patients who experience this complication following
PCI have increased risk of MI and death and morbidity
during the procedure (1,12). The exact mechanism of the no
reflow/slow flow phenomenon is not known, but it is
thought to stem from dysfunction or obstruction of the
microcirculation at the level of the resistance arterioles (13).
After PCI of the culprit lesion, no reflow/slow flow may
occur through spasm of the distal microcirculation, platelet
clumping, and the distal embolization of pieces of friable
lipid-rich plaque (14). No reflow/slow flow phenomenon
has been reported after rotablator for de novo and stent
restenotic lesions in patients on beta-blockers, suggesting
the contribution of microvascular unopposed alpha-agonism
in this abnormal phenomenon (15).
Many proposed treatments have been published for the
no reflow/slow flow phenomenon, including intracoronary
injections of verapamil, diltiazem, nitroglycerin, nitroprus-
side, nicorandil, urokinase, abciximab, adenosine, papaver-
ine, and intra-aortic balloon counterpulsation (12,16–22).
Despite many of these treatments proving successful, no
reflow/slow flow remains a problem, especially in degener-
ated SVGs in which no reflow/slow flow can occur in up to
20% of interventions, with unfavorable clinical outcome
(12). Hong et al. (23) observed that distal embolization with
associated no reflow/slow flow was an independent predic-
tor of late mortality and in-hospital major CK-MB eleva-
tion (odds ratio 4.4; 95% confidence interval 1.9 to 10.1) in
patients undergoing PCI for lesions in degenerated SVGs.
A marked reduction in major adverse cardiac events
(post-PCI myocardial infarction and “no reflow” phenom-
enon) was observed in PCI of degenerated SVGs with distal
protection in a recent prospective, randomized multicenter
study (3). However, ISR lesions in SVGs were excluded
from this trial.
In the present study of ISR lesions in degenerated SVGs,
we found no episodes of no reflow/slow flow and no
in-hospital MIs after PCI. The likely explanation for these
favorable results without distal embolic protection is that
the ISR lesions are pathologically distinct from de novo
lesions. De novo lesions in degenerated SVGs consist of
friable, atherothrombotic material with a high propensity to
embolize when manipulated during PCI, with ensuing
release of vasoactive substances (14,24). In sharp contrast,
ISR lesions are the result of neointimal formation alone
(7,25). Neointima is composed principally of proliferating
smooth muscle cells (5,6) and extracellular matrix (26).
Mural thrombus and soft lipid-rich elements have not been
found in neointimal formation in the pig model (27) or in
humans (28).
In the present study we indeed found the peri-PCI risk of
distal embolization and ischemic events to be rare after PCI
of ISR lesions in degenerated SVG without distal embolic
protection.
Study limitations. This study has several limitations. It is
a retrospective study from a single center. The study group
may have been subject to selection bias. The decision not to
use distal embolic protection was at the discretion of the
interventional cardiologist. Focal type I ISR lesions were
treated in over 50% of cases, although this is representative
of the proportion of focal ISR lesions treated in other ISR
treatment series. Diffuse ISR lesions made up 46% of cases
in our series. Lastly, the number of patients in our series is
relatively small.
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